Sodium fluoride f-18
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Dosing in kidney impairment
| Estimated Radiation Dose mGy/MBq | |||||
| Organ | Adult 70 kgData from Nuclear Regulatory Commission Report, Radiation Dose Estimates for Radiopharmaceuticals, NUREG/CR-6345, page 10, 1996. | 15 year 56.8 kgData from ICRP publication 53, Radiation Dose to Patients from Radiopharmaceuticals, Ann ICRP, Volume 18, pages15 and 74, 1987 | 10 year 33.2 kg | 5 year 19.8 kg | 1 year 9.7 kg |
|---|---|---|---|---|---|
| Adrenals | 0.0062 | 0.012 | 0.018 | 0.028 | 0.052 |
| Brain | 0.0056 | N/A | N/A | N/A | N/A |
| Bone surfaces | 0.060 | 0.050 | 0.079 | 0.13 | 0.30 |
| Breasts | 0.0028 | 0.0061 | 0.0097 | 0.015 | 0.030 |
| Gallbladder wall | 0.0044 | N/A | N/A | N/A | N/A |
| Stomach wall | 0.0038 | 0.008 | 0.013 | 0.019 | 0.036 |
| Small intestine | 0.0066 | 0.012 | 0.018 | 0.028 | 0.052 |
| Upper large intestine wall | 0.0058 | 0.010 | 0.016 | 0.026 | 0.046 |
| Lower large intestine wall | 0.012 | 0.016 | 0.025 | 0.037 | 0.063 |
| Heart wall | 0.0039 | N/A | N/A | N/A | N/A |
| Kidneys | 0.019 | 0.025 | 0.036 | 0.053 | 0.097 |
| Liver | 0.0040 | 0.0084 | 0.013 | 0.021 | 0.039 |
| Lungs | 0.0041 | 0.0084 | 0.013 | 0.020 | 0.039 |
| Muscle | 0.0060 | N/A | N/A | N/A | N/A |
| Ovaries | 0.011 | 0.016 | 0.023 | 0.036 | 0.063 |
| Pancreas | 0.0048 | 0.0096 | 0.015 | 0.023 | 0.044 |
| Red marrow | 0.028 | 0.053 | 0.088 | 0.18 | 0.38 |
| Skin | 0.0040 | N/A | N/A | N/A | N/A |
| Spleen | 0.0042 | 0.0088 | 0.014 | 0.021 | 0.041 |
| Testes | 0.0078 | 0.013 | 0.021 | 0.033 | 0.062 |
| Thymus | 0.0035 | N/A | N/A | N/A | N/A |
| Thyroid | 0.0044 | 0.0084 | 0.013 | 0.020 | 0.036 |
| Urinary bladder wall | 0.25 | 0.27 | 0.4 | 0.61 | 1.1 |
| Uterus | 0.019 | 0.023 | 0.037 | 0.057 | 0.099 |
| Other tissue | N/A | 0.010 | 0.015 | 0.024 | 0.044 |
| Effective Dose Equivalent mSv/MBq | 0.027 | 0.034 | 0.052 | 0.086 | 0.17 |
Preparation and administration
Prepare this dose
Your numbers for sodium fluoride f-18. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Radiation Safety - Patient Preparation To minimize the radiation-absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to ingest at least 500 mL of fluid immediately prior and subsequent to the administration of Sodium Fluoride F 18 Injection. Encourage the patient to void one-half hour after administration of Sodium Fluoride F 18 Injection and as frequently thereafter as possible for the next 12 hours.
Drug Preparation and Administration Calculate the necessary volume to administer based on calibration time and dose. Inspect Sodium Fluoride F 18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit. Do not administer Sodium Fluoride F 18 Injection containing particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations.
Aseptically withdraw Sodium Fluoride F 18 Injection from its container.
Imaging Guidelines Imaging of Sodium Fluoride F 18 Injection can begin 1 to 2 hours after administration; optimally at 1 hour post administration. Encourage the patient to void immediately prior to imaging the fluoride F 18 radioactivity in the lumbar spine or bony pelvis.
| Estimated Radiation Dose mGy/MBq | |||||
| Organ | Adult 70 kgData from Nuclear Regulatory Commission Report, Radiation Dose Estimates for Radiopharmaceuticals, NUREG/CR-6345, page 10, 1996. | 15 year 56.8 kgData from ICRP publication 53, Radiation Dose to Patients from Radiopharmaceuticals, Ann ICRP, Volume 18, pages15 and 74, 1987 | 10 year 33.2 kg | 5 year 19.8 kg | 1 year 9.7 kg |
|---|---|---|---|---|---|
| Adrenals | 0.0062 | 0.012 | 0.018 | 0.028 | 0.052 |
| Brain | 0.0056 | N/A | N/A | N/A | N/A |
| Bone surfaces | 0.060 | 0.050 | 0.079 | 0.13 | 0.30 |
| Breasts | 0.0028 | 0.0061 | 0.0097 | 0.015 | 0.030 |
| Gallbladder wall | 0.0044 | N/A | N/A | N/A | N/A |
| Stomach wall | 0.0038 | 0.008 | 0.013 | 0.019 | 0.036 |
| Small intestine | 0.0066 | 0.012 | 0.018 | 0.028 | 0.052 |
| Upper large intestine wall | 0.0058 | 0.010 | 0.016 | 0.026 | 0.046 |
| Lower large intestine wall | 0.012 | 0.016 | 0.025 | 0.037 | 0.063 |
| Heart wall | 0.0039 | N/A | N/A | N/A | N/A |
| Kidneys | 0.019 | 0.025 | 0.036 | 0.053 | 0.097 |
| Liver | 0.0040 | 0.0084 | 0.013 | 0.021 | 0.039 |
| Lungs | 0.0041 | 0.0084 | 0.013 | 0.020 | 0.039 |
| Muscle | 0.0060 | N/A | N/A | N/A | N/A |
| Ovaries | 0.011 | 0.016 | 0.023 | 0.036 | 0.063 |
| Pancreas | 0.0048 | 0.0096 | 0.015 | 0.023 | 0.044 |
| Red marrow | 0.028 | 0.053 | 0.088 | 0.18 | 0.38 |
| Skin | 0.0040 | N/A | N/A | N/A | N/A |
| Spleen | 0.0042 | 0.0088 | 0.014 | 0.021 | 0.041 |
| Testes | 0.0078 | 0.013 | 0.021 | 0.033 | 0.062 |
| Thymus | 0.0035 | N/A | N/A | N/A | N/A |
| Thyroid | 0.0044 | 0.0084 | 0.013 | 0.020 | 0.036 |
| Urinary bladder wall | 0.25 | 0.27 | 0.4 | 0.61 | 1.1 |
| Uterus | 0.019 | 0.023 | 0.037 | 0.057 | 0.099 |
| Other tissue | N/A | 0.010 | 0.015 | 0.024 | 0.044 |
| Effective Dose Equivalent mSv/MBq | 0.027 | 0.034 | 0.052 | 0.086 | 0.17 |
Drug interactions
Check sodium fluoride f-18 against a medication listLabel text (1 paragraph)
The possibility of interactions of Sodium Fluoride F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.
Contraindications
None. None (4).
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for sodium fluoride f-18. Check the label's hepatic warnings.
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Pregnancy Category C Any radiopharmaceutical including Sodium Fluoride F 18 Injection has a potential to cause fetal harm. The likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. Animal reproduction studies have not been conducted with Sodium Fluoride F 18 Injection. Prior to the administration of Sodium Fluoride F 18 Injection to women of childbearing potential, assess for presence of pregnancy. Sodium Fluoride F 18 Injection should be given to a pregnant woman only if clearly needed.
Lactation
8.3 Nursing Mothers It is not known whether Sodium Fluoride F 18 Injection is excreted into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of Sodium Fluoride F 18 Injection or not to administer Sodium Fluoride F 18 Injection, taking into account the importance of the drug to the mother. The body of scientific information related to radioactivity decay, drug tissue distribution and drug elimination shows that less than 0.01% of the radioactivity administered remains in the body after 24 hours (10 half-lives).
To minimize the risks to a nursing infant, interrupt nursing for at least 24 hours.
Breastfeeding (LactMed)
Information in this record refers to the use of sodium fluoride F 18 as a diagnostic agent. The manufacturer recommends withholding breastfeeding for 24 hours after a diagnostic dose of 300-450 MBq (8 to 12 mCi); however, this time might be longer than necessary given the minimal amount of fluoride that appears in breastmilk. Twenty-four hours is about 10 half-lives of fluoride F 18 and less than 0.01% of the radioactivity administered will remain in the body. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption. Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.